Low-dose Interleukin-2 and Pembrolizumab Among Patients With Metastatic Melanoma and Renal Cell Carcinoma
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Interleukin-2 (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms UVA-AM-002
- 09 Jul 2019 Planned initiation date changed from 16 Oct 2017 to 29 Oct 2018.
- 09 Jul 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 30 Oct 2018 Planned End Date changed from 1 May 2022 to 1 Oct 2023.